DCGI allows stickering of revised MRP on medical devices post GST reform

New Delhi:  The drug regulator has permitted the temporary affixing of stickers to reflect revised Maximum Retail Prices (MRPs) on certain medical devices to implement the revised GST rate.

As per the government’s decision, the GST rates on drugs and formulations have been reduced, with the new rates scheduled to take effect from September 22, 2025. In response to this revision, the Central Licensing Authority (CLA)—exercising powers under the Drugs and Cosmetics Act, 1940 and applicable rules—has issued a notification allowing both importers and domestic manufacturers to affix stickers with updated MRPs on Class C and Class D medical devices.

The CLA has clarified that this permission is granted solely to facilitate the implementation of the revised GST rates and will be valid for a period of three months from the date of the order.

During this period, manufacturers and importers may use stickers to display the corrected MRP on product packaging without requiring reprinting of the original packaging materials.

Related Posts

Mankind Pharma to Acquire 70% Stake in Belgium’s ACTx

Shares of Mankind Pharma fell more than 2% on 16 October after the company announced that it has signed an agreement to acquire a 70% stake in Belgium-based biotechnology company…

Can a drug licence be suspended before a hearing? Karnataka HC explains rule

NEW DELHI: Can a drug licensing authority suspend a pharmaceutical distributor’s licence while issuing a show-cause notice, before considering its response? The Karnataka high court has said the procedure under…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Mankind Pharma to Acquire 70% Stake in Belgium’s ACTx

Mankind Pharma to Acquire 70% Stake in Belgium’s ACTx

Can a drug licence be suspended before a hearing? Karnataka HC explains rule

Can a drug licence be suspended before a hearing? Karnataka HC explains rule

A Boy survives 18th Floor Fall, thanks to Yashoda Medicity

A Boy survives 18th Floor Fall, thanks to Yashoda Medicity

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs